Tyrosine kinase Src inhibitors: Potential therapeutic applications

被引:35
作者
Susa, M
Teti, A
机构
[1] Novartis Pharma AG, Dept Arthrit & Bone Metab, Bone Metab Unit, Res Bone Metab, CH-4002 Basel, Switzerland
[2] Univ Aquila, Dept Expt Med, Bone Biopathol Lab, I-67100 Laquila, Italy
[3] Univ Aquila, Sch Med, I-67100 Laquila, Italy
关键词
D O I
10.1358/dnp.2000.13.3.566664
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
More than 20 years after its discovery, tyrosine kinase Src is still the focus of intense research, in both academia and the pharmaceutical industry. A prototype for non-receptor tyrosine kinases and proto-oncogenes, Src also has a specific role in bone biology. Src's essential role in osteoclast-mediated hone resorption relies on its high expression in this cell type and on the presence of specific substrates, the identity of which is currently being unraveled. Recent identification of selective, potent and orally available Src family kinase inhibitors and their detailed characterization in cells and in animal models of bone loss has produced a new impetus and a novel tool in the field, Here we review the cellular and molecular mechanisms through which Src kinase inhibitors could find an application as therapeutics, particularly in the fields of bone and cancer-induced bone metastases. (C) 2000 Prous Science. All rights reserved.
引用
收藏
页码:169 / 175
页数:7
相关论文
共 60 条
[1]   Substrate recognition by osteoclast precursors induces c-src/microtubule association [J].
AbuAmer, Y ;
Ross, FP ;
Schlesinger, P ;
Tondravi, MM ;
Teitelbaum, SL .
JOURNAL OF CELL BIOLOGY, 1997, 137 (01) :247-258
[2]   Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor [J].
AbuAmer, Y ;
Ross, FP ;
Edwards, J ;
Teitelbaum, SL .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (06) :1557-1565
[3]   Involvement of focal adhesion kinase in invasin-mediated uptake [J].
Alrutz, MA ;
Isberg, RR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (23) :13658-13663
[4]  
ARGUELLO F, 1988, CANCER RES, V48, P6876
[5]  
Biscardi JS, 1999, ADV CANCER RES, V76, P61
[6]   Factors regulating the growth of metastatic cancer in bone [J].
Boyce, BF ;
Yoneda, T ;
Guise, TA .
ENDOCRINE-RELATED CANCER, 1999, 6 (03) :333-347
[7]   REQUIREMENT OF PP60C-SRC EXPRESSION FOR OSTEOCLASTS TO FORM RUFFLED BORDERS AND RESORB BONE IN MICE [J].
BOYCE, BF ;
YONEDA, T ;
LOWE, C ;
SORIANO, P ;
MUNDY, GR .
JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (04) :1622-1627
[8]   Regulation, substrates and functions of src [J].
Brown, MT ;
Cooper, JA .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1996, 1287 (2-3) :121-149
[9]   Structure-activity relationships of a novel class of Src SH2 inhibitors [J].
Buchanan, JL ;
Vu, CB ;
Merry, TJ ;
Corpuz, EG ;
Pradeepan, SG ;
Mani, UN ;
Yang, M ;
Plake, HR ;
Varkhedkar, VM ;
Lynch, BA ;
MacNeil, IA ;
Loiacono, KA ;
Tiong, CL ;
Holt, DA .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (16) :2359-2364
[10]   Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells [J].
Catlett-Falcone, R ;
Landowski, TH ;
Oshiro, MM ;
Turkson, J ;
Levitzki, A ;
Savino, R ;
Ciliberto, G ;
Moscinski, L ;
Fernández-Luna, JL ;
Nuñez, G ;
Dalton, WS ;
Jove, R .
IMMUNITY, 1999, 10 (01) :105-115